From the Journals

Port Delivery System With Ranibizumab for Diabetic Eye Disease

Researchers determined that the PDS may decrease the treatment burden of frequent intravitreal injections, but further research on efficacy and safety is needed.

Share

  • 1

    PAGODA and PAVILLION trials assessed Port Delivery System with ranibizumab.

  • 2

    PDS was noninferior to monthly intravitreal ranibizumab injections for diabetic macular edema.

  • 3

    Adverse events of special interest (AESI) were more common in the PDS group.

  • 4

    The PDS with ranibizumab 100 mg/mL was approved for DME in February

  • 5

    The PDS has potential to shift the treatment paradigm for diabetic retinal diseases.

Original Source(s)

Port Delivery System With Ranibizumab for Diabetic Eye Disease

Researchers determined that the PDS may decrease the treatment burden of frequent intravitreal injections, but further research on efficacy and safety is needed.

  • by Sarah Fackler

  • April 9, 2025

  • 7 min

Related Content

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Integration of Vision Services Remains an Unmet Need in FQHCs

Telemedicine, funding, and provider partnerships can help, researchers say.